ES3026158T3 - Peptide compounds and therapeutic uses of same - Google Patents

Peptide compounds and therapeutic uses of same Download PDF

Info

Publication number
ES3026158T3
ES3026158T3 ES19752749T ES19752749T ES3026158T3 ES 3026158 T3 ES3026158 T3 ES 3026158T3 ES 19752749 T ES19752749 T ES 19752749T ES 19752749 T ES19752749 T ES 19752749T ES 3026158 T3 ES3026158 T3 ES 3026158T3
Authority
ES
Spain
Prior art keywords
peptide
seq
peptides
amino acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19752749T
Other languages
English (en)
Spanish (es)
Inventor
Eran Ovadia
Avi Ben-Shimon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Pharma Ltd
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69141375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3026158(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Application granted granted Critical
Publication of ES3026158T3 publication Critical patent/ES3026158T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES19752749T 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same Active ES3026158T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Publications (1)

Publication Number Publication Date
ES3026158T3 true ES3026158T3 (en) 2025-06-10

Family

ID=69141375

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19752749T Active ES3026158T3 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Country Status (20)

Country Link
US (2) US11912790B2 (https=)
EP (2) EP3820882B1 (https=)
JP (2) JP7395517B2 (https=)
KR (1) KR102880543B1 (https=)
CN (1) CN112351989B (https=)
AU (2) AU2019300567B2 (https=)
BR (1) BR112020024748A2 (https=)
CA (1) CA3100961A1 (https=)
CO (1) CO2021001290A2 (https=)
EA (1) EA202190249A1 (https=)
ES (1) ES3026158T3 (https=)
HR (1) HRP20250746T1 (https=)
HU (1) HUE072141T2 (https=)
IL (2) IL317252A (https=)
MX (1) MX2021000264A (https=)
PL (1) PL3820882T3 (https=)
RS (1) RS66946B1 (https=)
SG (1) SG11202012773QA (https=)
WO (1) WO2020012478A2 (https=)
ZA (1) ZA202100587B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012773QA (en) 2018-07-11 2021-01-28 Immunity Pharma Ltd Peptide compounds and therapeutic uses of same
IL272074B2 (en) * 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
JPS4843906B1 (https=) * 1970-08-11 1973-12-21
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
EP1381839A4 (en) 2001-04-03 2005-10-12 Univ Leland Stanford Junior METHOD FOR THE IMAGE OF CELL DEOD IN VIVO
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
HUE024953T2 (en) * 2004-08-23 2016-02-29 Yeda Res & Dev Peptide inhibitors to mediate stress responses
JP2008528630A (ja) * 2005-02-01 2008-07-31 アテニュオン，エルエルシー 抗血管新生ｐｈｓｃｎペプチドを含む組成物
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
JP2013505230A (ja) * 2009-09-17 2013-02-14 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 酸化ストレス関連障害を処置するためのペプチド
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US20130331297A1 (en) * 2010-07-16 2013-12-12 Avantgen, Inc. Novel peptides and uses thereof
BR112013015797B1 (pt) * 2010-12-23 2021-08-31 Shell Internationale Research Maatschappij B.V. Organismo microbiano e método de produzir um derivado de acil-coa graxo
EP2715350B1 (en) * 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
CN104045703B (zh) * 2013-03-15 2021-04-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
US8802633B1 (en) * 2013-03-18 2014-08-12 Board Of Regents, The University Of Texas System Autophagy-inducing peptide analogs
ES2799404T3 (es) * 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos
US9453061B2 (en) * 2014-08-06 2016-09-27 Brown University Method and compositions for treatment of calcineurin-related diseases
CA2988388C (en) 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
SG11202012773QA (en) 2018-07-11 2021-01-28 Immunity Pharma Ltd Peptide compounds and therapeutic uses of same
IL272074B2 (en) 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Also Published As

Publication number Publication date
AU2019300567B2 (en) 2024-09-19
KR20210045397A (ko) 2021-04-26
RS66946B1 (sr) 2025-07-31
US20240190919A1 (en) 2024-06-13
ZA202100587B (en) 2022-07-27
WO2020012478A3 (en) 2020-02-20
WO2020012478A2 (en) 2020-01-16
IL317252A (en) 2025-01-01
EA202190249A1 (ru) 2021-05-21
PL3820882T3 (pl) 2025-08-11
US20210261615A1 (en) 2021-08-26
JP2024026217A (ja) 2024-02-28
KR102880543B1 (ko) 2025-11-04
JP7395517B2 (ja) 2023-12-11
EP3820882B1 (en) 2025-04-02
EP4566617A3 (en) 2025-10-01
JP7682248B2 (ja) 2025-05-23
HUE072141T2 (hu) 2025-10-28
SG11202012773QA (en) 2021-01-28
MX2021000264A (es) 2021-05-12
IL280101B1 (en) 2025-01-01
AU2019300567A1 (en) 2021-02-25
JP2021531246A (ja) 2021-11-18
US11912790B2 (en) 2024-02-27
CN112351989B (zh) 2024-03-26
BR112020024748A2 (pt) 2021-03-23
IL280101A (en) 2021-03-01
CN112351989A (zh) 2021-02-09
HRP20250746T1 (hr) 2025-08-15
CA3100961A1 (en) 2020-01-16
AU2024278477A1 (en) 2025-01-30
EP3820882A2 (en) 2021-05-19
IL280101B2 (en) 2025-05-01
CO2021001290A2 (es) 2021-02-26
EP4566617A2 (en) 2025-06-11
EP3820882C0 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
US11376305B2 (en) Compositions and methods for regulating blood pressure
JP7682248B2 (ja) ペプチド化合物およびその治療的用途
ES2932772T3 (es) Nuevos péptidos grapados y utilizaciones de los mismos
US9067970B2 (en) Anticancer agents comprising peptides with cancer-specific toxicity
JP6701083B2 (ja) 抗リンパ腫ペプチド
JP7809060B2 (ja) ペプチド化合物およびそれを用いる疾患の治療方法
US20230372551A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
US20230174582A1 (en) Vipr2 antagonist peptide
RU2812775C2 (ru) Пептидные соединения и их терапевтическое применение
WO2016151478A1 (en) Stapled peptides and uses thereof
US20220168383A1 (en) Neurotensinergic agonists and methods of using same preventing or treating pain
JP2018027911A (ja) 抗掻痒剤
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение
BR112018001207B1 (pt) Uso de um peptídeo no tratamento ou na prevenção de câncer